New diabetes combo shows promise in major trial
NCT ID NCT06235086
First seen Apr 30, 2026 · Last updated May 06, 2026 · Updated 2 times
Summary
This study tested a new injectable drug called TG103, taken with the common diabetes pill metformin, in 632 adults with type 2 diabetes. The goal was to see if TG103 helps lower blood sugar better than an existing drug (dulaglutide) over 28 weeks. Participants had poorly controlled diabetes despite taking metformin alone. The study measured changes in blood sugar levels and safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University People's Hospital
Beijing, Beijing Municipality, 100032, China
Conditions
Explore the condition pages connected to this study.